Analgesic substances derived from natural products (natureceuticals).
From the first recorded accounts, over 7000 years ago, various forms of natural products have been utilized to treat pain disorders. Prototypical examples of such natural products are the opium poppy (Papaver soniferum) and the bark of the willow tree (Salix spp.). It was not until the 19th century when individual compounds were isolated from these substances and were determined to posses the desired effects. The known sources of these substances have been thoroughly investigated. Over the last several decades, more analgesic substances have been purified from natural products resulting in novel structural classes and mechanisms of actions. Plants and other natural products described in historical ethnobotanical and ethnopharmacological literature have become of more recent interest in drug discovery efforts. These manuscripts and reports are being utilized to aid in the identification of natural products that have been historically employed in the alleviation of pain. A large factor that has highlighted the importance of discovering novel compounds to treat pain has been in the fundamental understanding of the complex mechanisms of pain transmission in the nervous system. Nociceptive processing involves many receptor classes, enzymes and signaling pathways. The identification of novel classes of compounds from natural sources may lead to advancing the understanding of these underlying pharmacological mechanisms. With the potential of uncovering new compounds with idealistic pharmacological profiles (i.e., no side effects, no addictive potential), natural products still hold great promise for the future of drug discovery especially in the treatment of pain disorders and potentially drug addictions.
McCurdy
Christopher R
CR
Department of Medicinal Chemistry, School of Pharmacy, National Center for Natural Products Research, Research Institute of Pharmaceutical Sciences, University of Mississippi, University, MS 38677, USA. cmccurdy@olemiss.edu
Scully
Stephen S
SS
D000700:Analgesics / Q000302:isolation & purification* / Q000494:pharmacology* / Q000627:therapeutic use; D000701:Analgesics, Opioid / Q000302:isolation & purification / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000302:isolation & purification / Q000494:pharmacology / Q000627:therapeutic use; D001241:Aspirin / Q000302:isolation & purification / Q000494:pharmacology / Q000627:therapeutic use; D001688:Biological Products / Q000737:chemistry* / Q000494:pharmacology*; D006801:Humans; D007473:Ion Channels / Q000187:drug effects; D010146:Pain / Q000188:drug therapy; D043882:Receptors, Cannabinoid / Q000187:drug effects; D011950:Receptors, Cholinergic / Q000187:drug effects; D050916:TRPV Cation Channels / Q000187:drug effects
D000700:Analgesics; D000701:Analgesics, Opioid; D000894:Anti-Inflammatory Agents, Non-Steroidal; D001688:Biological Products; D007473:Ion Channels; D043882:Receptors, Cannabinoid; D011950:Receptors, Cholinergic; D050916:TRPV Cation Channels; D001241:Aspirin